Sanofi Entered into a Research Collaboration with Scribe Therapeutics to Advance CRISPR-based Cell Therapies for Cancer
Shots:
- Scribe to receive $25M up front & will be eligible to receive ~$1B in development and commercial milestones along with royalties on net future product sales that emerge from the collaboration
- Sanofi gets the non-exclusive rights to use genome editing CasX-Editor (XE) technology for multiple oncology targets & selects Scribe’s CRISPR by Design platform to expand the oncology pipeline for ex vivo cell therapies
- The collaboration complements Sanofi’s robust research efforts for the NK cell therapy spectrum and provides access to scientists to use engineered CRISPR-based technologies for off-the-shelf NK cell therapies and novel combination
Ref: Bussinesswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
